Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Pregabalin - Lyrica - June 2004 in Europe

Posted by jlbl2l on March 31, 2004, at 10:00:37

Pfizer's LYRICA Receives Positive Opinion in Europe from Committee for Proprietary Medicinal Products


NEW YORK, March 25, 2004 -- Pfizer Inc said today that the Committee for Proprietary Medicinal Products (CPMP) adopted a positive opinion recommending marketing authorization of LYRICA® (pregabalin) in the European Union for the treatment of neuropathic pain and add-on therapy for partial seizures.

Following the CPMP's positive opinion, their recommendation will be reviewed by the European Commission (EC), which has authority to grant marketing authorizations for the European Union. Pfizer anticipates a final decision from the EC in June 2004.

Developed by Pfizer, pregabalin has a novel mechanism of action which allows treatment of certain neurologic and psychiatric disorders.

“We are pleased with the CPMP’s positive opinion of LYRICA and expect that marketing authorization will be granted by the European Commission,” said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. “LYRICA will be a new treatment option for neuropathic pain, which is a debilitating form of chronic pain that affects millions of Europeans. In addition, LYRICA will benefit patients suffering from epilepsy by providing better control of their seizures.”

Neuropathic pain, often characterized by a burning, tingling and/or shock-like sensation, is a type of chronic pain that is often misdiagnosed, under-treated, and a significant burden to sufferers, their families, and society. Epilepsy, a chronic neurological condition that is marked by seizures, affects an estimated 50 million people worldwide. Treatment that effectively controls or reduces the frequency of seizures has important consequences not only on the physical well-being and productivity of patients but also their quality of life.

Pregabalin is currently under review by the U.S. Food and Drug Administration for the management of neuropathic pain associated with diabetic peripheral neuropathy and herpes zoster (postherpetic neuralgia), as adjunctive therapy in the treatment of partial seizures, and for the treatment of generalized anxiety disorder in adults.

Though there are no comprehensive figures estimating the costs associated with neuropathic pain, the condition contributes significantly to direct healthcare costs and indirect costs such as worker productivity and absenteeism.

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best-known consumer products.



Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:jlbl2l thread:330778
URL: http://www.dr-bob.org/babble/20040329/msgs/330778.html